Adam MD - Alto Neuroscience, Chief Officer
| ANRO Stock | 4.31 0.22 5.38% |
Executive
Adam MD is Chief Officer of Alto Neuroscience,
| Age | 58 |
| Address | 369 South San Antonio Road, Los Altos, CA, United States, 94022 |
| Phone | 650 200 0412 |
| Web | https://www.altoneuroscience.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chau MBA | CytomX Therapeutics | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Meredith MBA | Soleno Therapeutics | 52 | |
| Amy CFA | Assembly Biosciences | N/A | |
| Patricia MPH | Soleno Therapeutics | 58 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| Jesse Schumaker | Soleno Therapeutics | N/A | |
| ScD MD | Moleculin Biotech | 72 | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Anuj MD | Assembly Biosciences | 46 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| PharmD MBA | Soleno Therapeutics | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
Alto Neuroscience, Leadership Team
Elected by the shareholders, the Alto Neuroscience,'s board of directors comprises two types of representatives: Alto Neuroscience, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alto. The board's role is to monitor Alto Neuroscience,'s management team and ensure that shareholders' interests are well served. Alto Neuroscience,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alto Neuroscience,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Smith, CFO Secretary | ||
| Melissa Berman, Vice Accounting | ||
| Amit MD, Chairman Founder | ||
| Michael MBA, Chief Officer | ||
| Wei Wu, CoFounder Officer | ||
| Jason Hoffman, Vice Resources | ||
| Erin JD, General Officer | ||
| Adam MD, Chief Officer | ||
| B BCom, CoFounder CEO | ||
| Fadi MD, Senior Innovation | ||
| Jessica Powell, Chief Officer |
Alto Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alto Neuroscience, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 184.12 M | ||||
| Shares Outstanding | 26.96 M | ||||
| Shares Owned By Insiders | 13.11 % | ||||
| Shares Owned By Institutions | 75.03 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Book | 2.04 X | ||||
| EBITDA | (34.56 M) | ||||
| Net Income | (36.3 M) | ||||
| Total Debt | 151.46 M | ||||
| Book Value Per Share | 6.67 X |
Pair Trading with Alto Neuroscience,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Moving together with Alto Stock
Moving against Alto Stock
| 0.74 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.71 | GILD | Gilead Sciences | PairCorr |
| 0.61 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.58 | KTTAW | Pasithea Therapeutics | PairCorr |
| 0.36 | KZR | Kezar Life Sciences | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.